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ABSTRACT
Pediatric tumors arise upon oncogenic transformation of stem/progenitor cells 
during embryonic development. Given this scenario, the existence of non-tumorigenic 
stem cells included within the aberrant tumoral niche, with a potential role in tumor 
biology, is an intriguing and unstudied possibility. Here, we describe the presence 
and function of non-tumorigenic neural crest-derived progenitor cells in aggressive 
neuroblastoma (NB) tumors.  These cells differentiate into neural crest typical 
mesectodermal derivatives, giving rise to tumor stroma and promoting proliferation 
and tumor aggressiveness. Furthermore, an analysis of gene expression profiles in 
stage 4/M NB revealed a neural crest stem cell (NCSC) gene signature that was 
associated to stromal phenotype and high probability of relapse. Thus, this NCSC gene 
expression signature could be used in prognosis to improve stratification of stage 
4/M NB tumors. Our results might facilitate the design of new therapies by targeting 
NCSCs and their contribution to tumor stroma.
INTRODUCTION
Neuroblastomas (NBs) are embryonic tumors 
arising during development from sympathoadrenal cells 
of the neural crest (NC) [1]. They are the most common 
extra-cranial solid tumors in children, being responsible 
for approximately 7–10% of pediatric cancers and 15% of 
all pediatric cancer deaths [2]. NBs are characterized by 
high heterogeneity within tumor phenotypes, ranging from 
spontaneous regression in stage 4S/MS low risk patients, 
to high-risk stage 4/M tumors that frequently present 
with metastasis and rapidly develop resistance to current 
treatments [1, 3]. In addition to the age at diagnosis, some 
genetic abnormalities have been described as prognostic 
for high risk NB, such as ploidy, amplification of MYCN 
oncogene, and gain or loss of some chromosomal regions 
[3].
In the past few years, the role of tumor stromal 
cells has emerged as a key point for the biology of 
several tumors [4]. Stromal cells have been described 
as important players in tumorigenesis, increasing tumor 
proliferation and angiogenesis [5], or selecting tumor 
cell clones responsible for distant metastasis [6–8]. 
Cancer associated fibroblasts (CAFs) are one of the most 
abundant components of tumor stroma [9]. Characterized 
by the expression of typical mesenchymal markers, such 
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as SMA, Vimentin, Thy1 (CD90) or FSP1 (S100A4) 
[4, 9], the origin and nature of these cells is not well 
known. In NB, SMA positive CAFs are inversely 
correlated with histological features associated to low risk 
tumors [10]. Moreover, a gene signature characterized 
by the presence of mesenchyme related genes defines a 
subgroup of NBs with increased metastatic potential and 
poor prognosis [11]. This mesenchymal aggressive stroma 
should not be confounded with the neural schwannian 
stroma, also described in NB [10], which is rather based 
on schwann cells and associated to benign prognosis.
The NC is a transient embryonic multipotent cell 
compartment with the potential to differentiate into 
neural cells, but also into mesectodermal derivatives, 
such as chondrocytes, adipocytes, osteocytes and smooth 
muscle cells [12, 13].  Herein, we investigate whether NC 
progenitors could be found within aggressive NB tumor 
microenvironment, potentially contributing to tumor 
stroma formation by differentiating into mesectodermal 
derivatives, such as SMA positive cells. Our findings 
could help to understand a subset of aggressive NB tumors 
characterized by rich mesenchymal stroma and a neural 
crest gene-expression profile.
RESULTS
Isolation and characterization of primary cell 
cultures from NB tumor biopsies
Aggressive NB tumor biopsies (Supplementary 
Table 1) were dissociated to single cells and cultured 
in ultra-low binding plates with neural crest medium 
[14], either directly or after a passage in adherent 
conditions (Figure 1A; see also Supplementary Figure 1). 
Resulting neurospheres were finally cultured in adherent 
conditions, again with neural crest specific medium 
(Supplementary Figure 1). As previously described [15], 
adherent conditions generally select for cells with stromal 
phenotype (Figure 1B). In contrast, neuroblasts only grew 
in suspension as spheres but tended to differentiate when 
attached to the substrate, disappearing from subsequent 
passages, indicating that our adherent primary culture 
protocol clearly favors the growth of stroma-like cells (see 
Supplementary Figure 1). On the other hand, the passage 
in low binding conditions (Supplementary Figure 1) is 
likely selecting for NS-forming NC-derived progenitor 
cells, which continue to grow after culturing onto adherent 
due to their stromal phenotype. Moreover, thanks to the 
neurosphere-forming passage, not any stromal cell found 
within tumors is present in our final adherent cultures. 
In fact, primary adherent cells obtained from tumor 
samples were negative for the expression of fibroblast 
specific antibody TE-7 [16], discarding the presence 
of patient derived-mesodermal fibroblasts (Figure 1C). 
Consistently, adherent cultures contained positive cells 
for smooth muscle actin alpha (aSMA), a typical NC 
marker that appears upon progenitor differentiation into 
mesenchymal lineages in adherent conditions [14, 17]. In 
addition, adherent primary cells expressed other typical 
NC markers such as p75/CD271, EDNRB, Nestin, GD2, 
CD44 or CD90 [18–20] (data not shown). Together, these 
results support the idea that our primary cultures are not 
simple mesodermal fibroblasts, but they rather consist of 
enriched NC-derived progenitor cells and their derivatives 
of mesectodermal lineage.
Next, we compared the expression profile of a tumor 
sample (NB5t) with its primary cells obtained in adherent 
conditions (Figure 1D). We focused on genes typical of 
mesenchymal or neural phenotypes, with special attention 
to genes enriched in neural crest stem cells (NCSCs) 
[13]. As expected, NB5t primary cells showed increased 
expression of mesenchymal genes (NT5E, ENG, ACTA2, 
MME, CD44, VIM or ALPL) [13, 18, 21, 22], while NB5t 
tumor sample expressed mostly neuronal genes (TH, 
ENO2, NCAM1, DDC or CHGB) [23–27] reflecting the 
neuroblastic phenotype of stage 4/M NB tumors. Genes 
over-expressed in NC progenitors were enriched in both 
samples, but with a clear difference between the two 
groups: NB5t primary cells showed high expression of 
NCSC genes related to the mesenchymal phenotype of 
the NC (such as S100A10, EDNRA or TGFB1) [28–30], 
while NB5t tumor sample was enriched in NCSC genes 
related to neural differentiation (PHOX2B and CHGA) 
[31, 32]. Based on these results, we extended this 
phenotypic analysis to 5 stage 4/M NB primary cell 
cultures (NB5t, NB14t, NB27t, NB32t, and NB50t) and 
3 established NB commercial cell lines with neuroblastic 
phenotype (SK-N-SH, IMR32 and SK-N-DZ). Using 
flow cytometry, we determined the expression of surface 
markers typical of neuronal cells (CD56/NCAM1 and 
CD57/HNK1) [14, 24, 26], mesenchymal cells (CD10/
MME, MSCA1/ALPL, CD44 and CD105/ENG) [13, 21, 
22, 33], and neural crest stem cells (CD271/p75) [13] 
(Figure 1E–1G). Despite the variability observed between 
different samples, the results confirmed that primary 
adherent cells obtained from NB tumor biopsies, in contrast 
to commercial cell lines, present a stromal phenotype 
characterized by high expression of typical mesenchymal 
proteins and low expression of neuronal markers. 
NB primary cultures contain a subpopulation of 
neural crest progenitor cells
NC derived progenitors can be found in postnatal 
tissues, and are characterized by the expression of 
the glial fibrillary acidic protein (GFAP) [14, 17]. NB 
primary adherent cultures presented cells double positive 
for GFAP and Nestin, an intermediate filament expressed 
in proliferating neural stem cells [34] (Figure 2A). 
Consistently, most adherent cells also expressed the neural 
stem cell typical transcription factor Sox2 [35] (inset in 
Figure 2A). The GFAP/Nestin double positive phenotype 
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was also found, at a reasonable frequency (1.2 ± 0.3%; 
n = 14 tumor samples), in the original tumor tissue 
(Figure 2B). To confirm the existence of NC derived 
progenitors in NB primary cultures, cells were challenged 
to form spheres in low binding substrate [36]. All NB 
samples tested formed spheres that were able to self-
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renew and that showed a remarkable increase in the 
percentage of GFAP/Nestin double positive cells (Figure 
2C–2E). Moreover, spheres showed a clear increase in 
the expression of genes typical for NC progenitors, such 
as BMI1, MSI1 and OCT4 [37, 38] (Figure 2F–2H), 
indicating a clear enrichment in NC-derived progenitor 
cells.
We next determined the phenotype of proliferative 
cells in NB primary cultures. 74.8 ± 6.7% of all cells 
undergoing mitosis in adherent conditions (identified by 
the presence of mitotic figures; Supplementary Figure 2) 
were positive for GFAP and Nestin, indicating a major 
role of double positive progenitor cells in proliferation 
and growth of primary cultures. In addition, we observed 
putative asymmetric cell divisions within the proliferating 
population, an evolutionary conserved division mode used 
by stem and progenitor cells [39] (see Supplementary 
Figure 2).
Endothelin-1 increases survival and proliferation 
of neural crest progenitors
Endothelin-1 (ET1) is a cytokine that regulates 
proliferation, migration, differentiation and survival of 
NC cells [19, 40]. Moreover, our group has previously 
shown a strong positive effect of ET1 on the proliferation 
of adult neural crest stem cells in the carotid body [41]. 
The addition of ET1 increased the number and diameter 
of spheres obtained from NB primary cultures, compatible 
with an increase in survival and proliferation of progenitor 
cells (Figure 2I, 2J, and Supplementary Figure 3). Gene 
expression profiling of spheres cultured from three 
different adherent primary cell samples revealed that 
ET1 treatment induced changes in the expression of 660 
genes, from which 458 were up regulated. As expected, 
Ingenuity Pathway Analysis of differentially expressed 
genes revealed an increase in bio-functions related to 
cell survival, viability and proliferation. Interestingly, the 
analysis also uncovered functions assigned to cell types 
closely related to the NC, such as chondrocytes, smooth 
muscle, neurons or cardiovascular tissues (Figure 2K, 
2L). Altogether, sensitivity to ET-1 and gene expression 
profiling analysis support a neural crest-derived stem cell 
phenotype in NS-forming progenitor cells cultured from 
NB adherent primary cells.
Neural crest progenitors can differentiate into 
both neural and mesectodermal lineages
The NC is a multipotent embryonic structure with 
the potential to differentiate to neural cells, but also to 
mesectodermal derivatives [12]. In addition, our group 
has recently described that neural crest progenitors in the 
adult carotid body retain this multipotentiality [42, 43]. 
To further characterize NB derived primary cells, we 
tested the differentiation capacity of these cells in vitro 
(Figure 2M, and Supplementary Figure 4) using different 
serum conditions (see Methods). Staining with both neural 
and mesenchymal markers revealed that NB spheres 
contained progenitor cells that were able to differentiate 
into neural cells (positive for GFAP, S100b, DDC or Tuj1), 
but also into typical mesenchymal-like derivatives, with 
a remarkable expression of SMA, a marker widely used 
to label cancer associated fibroblasts [4, 9]. Altogether, 
our results are fully compatible with the existence of a 
subpopulation of neural crest derived progenitor cells in 
NB tumor biopsies. These progenitors generate primary 
cell cultures with characteristic mesectodermal stromal 
phenotype.
Neural crest progenitors isolated from NB 
biopsies are not tumorigenic
At this point, we wondered whether these neural 
crest progenitor cells behaved as cancer stem cells, 
being tumorigenic and able to recapitulate patient tumor 
formation in immunocompromised mice. Cells from 
six different primary cultures were xenografted both 
subcutaneously and orthotopically (in the adrenal medulla) 
of immunosuppressed mice. Surprisingly, none of the 
mice developed tumors (Supplementary Table 2), despite 
the highly efficient tumorigenesis exhibited in the same 
assay by an IMR32 cell line positive control. Genomic 
analysis of these NB primary stromal cells revealed the 
absence of NB characteristic genomic alterations, such 
as MYCN amplification (sample NB5t), as compared to 
Figure 1: Characterization of stromal phenotype in primary adherent cell cultures isolated from stage 4/M NB tumor 
biopsies. (A) Schematic view of cell isolation protocol from tumor biopsies. (B) Representative bright field images of primary adherent 
cells isolated from two different NB biopsies (NB5t and NB14t) showing the characteristic stromal-like phenotype of cultured cells. (C) 
Inmunofluorescent labeling of mesoderm-derived fibroblasts with TE-7 marker, or neural crest-derived myofibroblasts with smooth muscle 
actin (SMA) in a control human fibroblast cell line (hFIB) and in three different NB tumor-derived cell cultures (NB5t, NB14t and NB27t). 
(D-G) Primary cells expressed mesenchymal-like but not neuroblastic markers. (D) Gene expression analysis comparing a NB primary cell 
culture (blue bars) and its original tumor sample (orange bars) (NB5t). Genes were selected according to their relationship to mesectodermal 
or neuroblastic phenotypes and their reported enrichment in neural crest stem cells (see text for references). Based on this result, a panel of 
surface markers was selected to extend the gene expression analysis to 5 NB primary cell cultures and 3 NB commercial cell lines with a 
reported neuroblastic phenotype. (E) Representative flow cytometry plots showing expression of MSCA1, CD44 (mesenchymal markers), 
CD56 and CD57 (neuroblastic markers) in NB primary adherent cells from NB5t tumor and in the neuroblastic cell line IMR32. (F) 
Analysis of flow cytometry data showing the expression level (% of positive cells) for each surface marker tested in each NB tumor derived 
primary cell culture or in NB commercial cell lines. (G) Quantification of data shown in (F) (*p < 0.05, Mann-Whitney U-test), comparing 
primary cells versus cell lines. Scale bars in (B) and (C): 100 µm.
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original tumors. Multiplex Ligation-dependent Probe 
Amplification (MLPA) analysis confirmed that NB 
primary adherent cells lacked some of the chromosomal 
aberrations present in tumor biopsies (Supplementary 
Figure 5). These results confirmed that, despite their 
neural crest origin, these NB tumor-derived progenitor 
cells lack critical genomic alterations, which could explain 
the absence of tumorigenicity. 
NB primary stromal cells increase proliferation 
of NB cell lines in vitro and promote tumor 
growth in a xenograft model in vivo
We next asked whether these tumor-derived neural 
crest progenitor cells could affect the biology and behavior 
of other NB tumor cells. We performed co-cultures 
of IMR32 commercial cell line with or without cells 
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from four different primary cell cultures (NB5t, NB14t, 
NB21t, and NB27t). In all cases, co-cultures increased 
proliferation of IMR32 cells (Figure 3A–3C). In order to 
have a glimpse of the type of paracrine signaling being 
established between primary cells and tumorigenic 
IMR32 cells, we repeated the co-culture experiments in 
the presence of specific inhibitors (Figure 3D). Stromal 
cells typically secrete both SDF-1 and TGFβ cytokines. 
AMD3100 is an inhibitor of CXCR4 receptor [44], which 
has been involved in malignant progression of NB through 
SDF-1 signaling [45], and PAN-TGFβ is an antibody that 
blocks TGFβ signaling [46]. Our results preliminarily 
suggest that SDF-1/CXCR4 signaling is important when 
promoting IMR32 proliferation, while TGFβ signaling 
seems to inhibit this proliferation (Figure 3D). These 
signaling routes constitute interesting examples of how 
primary adherent stromal cells might be regulating the 
aggressive behavior of IMR32 cells in vitro.
The co-culture results obtained in vitro prompted 
us to investigate a potential role of these NC progenitor-
derived stromal cells in promoting tumorigenesis in vivo. 
IMR32 cells were injected subcutaneously alone or with 
EGFP expressing primary cells from NB5t sample at a 
1:1 ratio (Figure 3E). Tumor supplementation with NC 
derived stromal cells caused a significant increase in tumor 
size (Figure 3F–H). Flow cytometry (Figure 3I, 3J) and 
immunohistochemistry (Figure 4A) confirmed that EGFP 
expressing NC derived primary cells were incorporated 
into tumor structure. Almost 100% of EGFP positive cells 
within tumor parenchyma were positive for SMA (Figure 
4B), and showed characteristic perivascular localization 
(Figure 4C). In addition, immunohistochemistry analysis 
revealed that NB primary cell supplementation caused a 
significant increase in SMA expression (Figure 4D, 4E), 
confirmed by qPCR (Figure 4F). In addition to ACTA2 
(SMA), expression analysis showed a significant increase 
in genes related to a mesenchymal phenotype, such as 
CD44, ENG, S100A10, TGFB1 and VIM (Figure 4F). 
Interestingly, expression levels of ACTA2, S100A10 
and VIM were positively and significantly correlated to 
tumor size, suggesting a relationship between NC derived 
stromal component and tumor growth (Figure 4G).
Neural Crest Stem Cell gene signature is 
associated to increased aggressiveness in stage 
4/M neuroblastoma
The results obtained led us to consider the 
existence of a specific neural crest stem cell (NCSC) 
genetic profile linked to mesenchymal phenotype and 
poor prognosis in stage 4/M NB. A set of 214 stage 4/M 
tumors [47] was analyzed in silico (see Methods). K-mean 
clustering based on the expression of genes up-regulated 
in NCSCs [13] generated three different groups with 
high, intermediate and low expression of NCSC gene 
signature (NCH, NCI and NCL respectively) (Figure 
Figure 2: Stage 4/M NB tumor-derived primary cultures contain a subpopulation of neural crest progenitor cells. (A) 
Representative photomicrograph showing nuclei (DAPI; blue), Nestin (green) and GFAP (red) stainings in a NB tumor derived primary 
adherent culture. Nestin/GFAP double positive cells are pointed with yellow arrows. Inset: Expression of Sox2 (green) in NB5t primary 
adherent cells. Scale bar: 100 µm (B) Representative picture showing the existence of GFAP/Nestin double positive cells (yellow arrows) 
in an original high-risk NB tumor tissue. Scale bar: 25 µm. (C) Primary cultures contain a subpopulation of cells that grow as spheres 
when cultured in non-adherent conditions. The bright field image on top shows typical spheres formed when NB tumor-derived adherent 
primary cells were cultured in low-binding conditions. Graph quantifies sphere-forming efficiency from 4 different tumor-derived samples, 
measured in primary, secondary and tertiary sphere passages, revealing the existence of a small but self-renewing fraction of sphere-
forming progenitor cells. (D) Immunocytochemistry showing nuclei (DAPI; blue), Nestin (green) and GFAP (red) expression in cells 
from adherent cultures and from spheres grown in parallel. Nestin/GFAP double positive cells are pointed with yellow arrows. Scale bar: 
100 µm (E) Quantification of GFAP/Nestin double positive cells from 3 different primary cultures (NB5t, NB14t and NB27t) and their 
corresponding spheres. In general, spheres showed a clear increase in the percentage of double positive cells (from 5% to 31%) (**p < 0.01, 
Student’s t-test). (F–H) Spheres are enriched in genes described as neural crest stem cell markers when compared to adherent cell cultures. 
(F) Quantitative PCRs showing a clear increment in the expression of Bmi1, Msi1 and Oct4 mRNAs (neural crest stem cell markers) in 
spheres when compared to their corresponding adherent cultures (level 1 line). The variability observed could be explained by tumor 
heterogeneity between patients. (G, H) Increase in mRNA expression was confirmed at protein level in primary cell cultures from tumor 
biopsy NB14t. (G) Immunohistochemistry showing the expression of Nestin (green) and Bmi1, Msi1 or Oct4 (red) in primary cell adherent 
cultures and spheres grown in parallel. Scale bars: 100 µm (H) Quantification of expression levels based on the intensity of fluorescence 
(arbitrary units normalized to adherent) confirmed the increase in neural crest stem cell marker mRNA expression shown in (F) (*p < 
0.05, Student’s t-test). (I–L) Endothelin-1 (ET-1) increases survival and proliferation of neural crest progenitors within primary cultures. 
(I) Representative bright field images of spheres cultured in control conditions or after ET-1 treatment. (J) Top. Quantification of sphere-
forming cell frequency illustrating how ET-1 increases the % of these cells in all primary cultures tested. Bottom. Quantification of sphere 
diameter showing how two of the three primary cell cultures also present a small but significant increase in sphere diameter when treated 
with ET-1. Both analyses together suggest an increase in survival and proliferation of neural crest progenitors treated with ET-1. (K, L) ET-1 
mediated effect was confirmed by gene expression profiling of control and ET-1 treated spheres from three different primary cell cultures. 
(K) Hierarchical clustering and scatter plot obtained from a microarray gene expression analysis performed to compare control versus ET-1 
treated spheres. (L) Ingenuity Pathway Analysis of genes differentially expressed (660 genes) after ET-1 treatment, predicting an increase in 
biofunctions like cell viability and cell survival, as well as in functions fully compatible with a neural crest origin of the spheres analyzed. 
(M) Immunofluorescent stainings of NB tumor-derived spheres after 4–5 days of differentiation in adherent conditions, with or without 
15% serum. Cells were labeled with antibodies against nestin (stem cell marker), SMA (mesenchymal differentiation marker), S100b and 
GFAP (glial differentiation markers), and DDC and Tuj1 (neuronal differentiation markers). Scale bars: 100 µm.
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Figure 3: NB tumor-derived adherent cells increase proliferation of NB cell lines in vitro and favor tumor growth in 
vivo. (A) Diagram of the experimental design of in vitro co-cultures. IMR32 NB cells expressing a red fluorescent protein (IMR32-RFP) 
were cultured alone or with NB tumor-derived adherent cells at 1:1 ratio. After 4 days in culture, the % of IMR32-RFP proliferative cells 
(PHH3+) was measured. (B) Representative fluorescent images of cultures showing nuclei (blue), proliferative cells (PHH3+; green) and 
IMR32-RFP cells (red fluorescent protein+; red). Scale bars: 100 µm. (C) Quantification of the % of PHH3+ IMR32-RFP cells in control 
(IMR32-RFP cells cultured alone) and in co-cultures with adherent cells derived from 4 different NB tumors (NB5t, NB14t, NB21t and 
NB27t). Results are normalized to the % of PHH3+ cells in control cultures (*p < 0.05; **p < 0.01; ***p < 0.001, Student’s t-test). (D) 
Quantification of IMR32-RFP proliferative cells (PHH3+) in co-cultures with NB5t cells, in the presence of AMD3100 and PAN-TGFβ 
inhibitors, always compared to control co-culture in the presence of vehicle (DMSO) (**p < 0.01; ***p < 0.001, Student’s t-test). (E) 
Experimental design of co-xenografts. (F) Representative image of a mouse xenografted with IMR32 cells alone (control xenograft, left 
flank) or admixed with NB5t derived adherent cells (co-xenograft, right flank). (G) Examples of different tumors after 2 months of growth, 
illustrating the bigger sized phenotype of co-xenografts. Scale bars: 10 µm. (H) Quantification of tumor weight in control and co-xenograft 
tumors. (*p < 0.05, Mann-Withney U-Test). (I) Representative flow cytometry plots showing the incorporation of a small but consistent 
% of EGFP positive NB derived stromal cells in co-xenograft tumors. (J) Quantification of EGFP positive cells (%) in control and co-
xenograft tumors (p = 0.057, Mann-Whitney U-Test).
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Figure 4: NB tumor-derived adherent cells give rise to SMA+ perivascular stromal cells in vivo. (A) Representative 
images of anti-EGFP immunohistochemistry in control and co-xenograft tumors. Tumors supplemented with primary adherent cells (lower 
panels) show EGFP positive cells (insets 1–4) with characteristic stromal cell morphology. Scale bars: 100 µm. (B) Immunofluorescent 
images detecting nuclei (blue), EGFP (green) and SMA (red) in two different co-xenografts. EGFP+ cells differentiate into SMA positive 
cells (yellow arrowheads) usually associated to other SMA+ cells (red arrowheads). Some of the double positive cells show characteristic 
perivascular localization (Co-XENO #132). Scale bars: 10 µm (C) Representative immunofluorescent picture of a co-xenograft tumor 
detecting EGFP (green) and an endothelial cell-specific lectin (GSA I; red), illustrating the typical perivascular localization of primary 
adherent cells. Scale bar: 50 µm. (D) Immunohistochemistry against SMA in sections of control and co-xenograft tumors. Images were 
binarized (right panels) and the % of SMA positive area quantified. Scale bars: 100 µm. (E) Quantification of the % of SMA positive area 
in control and co-xenograft tumors (**p < 0.01, Mann-Whitney U-Test). (F, G) Tumor supplementation with NB5t derived stromal cells 
increase the expression of mesenchymal-like genes. (F) Quantitative PCR analysis of the expression of mesenchymal genes in control and 
co-xenograft tumors. Expression levels of ACTA2 (encoding for SMA), CD44, ENG, MEF2C, S100A10, TFGB1 and VIM mRNAs are 
shown normalized to their expression in control tumors (*p < 0.05, Student’s t-test). (G) Correlation analysis of tumor weight (of both 
control and co-xenografts) versus mRNA expression levels of ACTA2, S100A10 and VIM (relative to GAPDH) (r = Pearson’s correlation 
coefficient). These correlations indicate that the higher the expression of mesenchymal markers the bigger the tumor size.
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5A, 5B). The analysis of transcriptome-wide profiles by 
principal component analysis confirmed the existence 
of clear differences between these three groups, with a 
maximum segregation between NCH and NCL tumors 
through principal component 2 (Figure 5C). In addition, 
NCH and NCL tumors showed increased aggressiveness 
and high probability of relapse when compared to NCI 
(Figure 5D). Next, we focused on NCH tumors and 
analyzed the expression of typical mesenchymal genes 
such as NT5E (CD73), ENG, CD44, PDGFRA, ACTA2 
(SMA), VIM, CXCL12 or SPARC. The levels of all 
these mesenchymal genes were significantly increased 
in NCH tumors when compared to NCL and NCI tumors 
together (NCL+I for brevity) (Figure 5E). Moreover, we 
carried out a parametric analysis of gene set enrichment 
(PAGE) comparing the expression of known gene set 
profiles in NCH versus NCL+I tumors. Interestingly, 
within the most highly enriched gene sets in NCH tumors, 
we found gene signatures typical of the mesenchymal 
subtype in glioblastoma [48] and the mesenchymal 
transition signature associated to cancer [49] (Figure 
5F–5H). In addition, compatible with an increase in 
NCSC genes related to the mesenchymal phenotype, we 
also detected enrichment in genes up regulated in human 
stromal stem cells (SSCs; Figure 5F–5H) [50]. Next, we 
wondered about the putative role of such a mesenchymal 
component in increasing tumor aggressiveness. To try 
to solve this question, we determined the genes that 
were differentially expressed between NCH and NCL+I 
tumors and performed a gene ontology analysis to reveal 
the biological significance of the different expression 
profiles. Interestingly, NCH tumors showed a significant 
enrichment in biofunctions like “cell proliferation”, 
“migration” and cellular processes related to the stromal 
component of tumors [4], such as “immune response”, 
“extracellular matrix organization”, “proliferation of 
endothelial cells”, “proliferation of smooth muscle 
cells” and “angiogenesis” (Figure 5I, 5J). Altogether, 
this in silico analysis suggests that a neural crest-derived 
progenitor component within aggressive NB tumors 
promotes the formation of mesectodermal stroma, with 
subsequent facilitation of angiogenesis and other processes 
necessary for tumor growth.
Expression of SMA correlates with NCSC gene 
signature and is associated to histopathological 
features of aggressive neuroblastomas
SMA is a typical marker of cancer-associated 
fibroblasts (CAFs), one of the most abundant components 
of tumor stroma [4, 9]. Immunohistochemistry of patient 
derived tumor samples (Supplementary Table 3) revealed 
a clear association between SMA expression (measured as 
% of SMA positive area) and histopathological features 
of aggressive tumors and bad prognosis (Figure 6A, 6B). 
Moreover, since chemotherapy treatment is associated to 
an acquired benign histopathology [51], post-treatment 
tumors exhibit a decrease in SMA expression (Figure 
6C, 6D). In silico analysis of 214 stage 4/M tumors [47] 
showed a high level of correlation between the expression 
of ACTA2 (SMA) and other mesenchymal genes such as 
ENG, TGFB1, S100A10 and VIM (Figure 6E). Based 
on the ability of NC progenitor cells to give rise to SMA 
positive mesectodermal derivatives [12, 13], we wondered 
whether ACTA2 expression could be used as a predictor 
of NCSC gene signature enrichment in NB tumors. 
PAGE analysis revealed that tumors with high expression 
of ACTA2 were enriched in NCSC genes, as well as in 
stromal stem cell genes (Figure 6F, 6G). In addition, 
ACTA2 expression and NCSC signature enrichment 
average z-scores showed a positive correlation (Figure 
6H, 6I). Moreover, the expression level of ACTA2 was 
significantly associated with poor prognosis (Figure 6J), 
revealing again a close relationship between mesenchymal 
features, NCSC signature enrichment and tumor 
aggressiveness. Combining tumor segregation based on 
NCSC gene signature enrichment and ACTA2 expression 
level, we observed that most NCH tumors (86%) express 
high levels of ACTA2, while most NCL samples (76%) 
belong to the ACTA2 low expression group, which is in 
agreement with the role of NCSCs giving rise to ACTA2 
expressing stromal cells. Interestingly, SMA expression 
segregates NCSC Intermediate tumors (NCI) into two 
groups with different event-free survival probability 
(Figure 6K). ACTA2 highly expressing NCI tumors 
(48%) show a low event-free survival probability, similar 
to tumors belonging to NCH and NCL groups, when 
compared to ACTA2 low expressing NCI tumors (52%). 
Together, these results support the interest of SMA 
staining and ACTA2 expression levels as prognostic 
markers associated to NC derived stromal content in NB 
tumors. Therefore, combination of these two analyses, NC 
gene signature and ACTA2 expression, results in a highly 
accurate stratification of stage 4/M tumors in terms of 
aggressiveness.
DISCUSSION
In the present study, we describe the existence of 
neural crest (NC) derived stem-like cells in aggressive 
neuroblastoma (NB) primary tumors. Cancer stem cells 
(CSCs) have become a major focus in cancer research 
for the last decade. Such an interest lies in the ability 
of these cells to initiate and propagate tumors, as well 
as their resistance to conventional treatments [52, 53]. 
NBs are embryonic tumors arising from cells belonging 
to the sympathoadrenal lineage of the NC [1]. Existing 
data suggest that malignant transformation can occur 
at any developmental stage of sympathoadrenal neural 
crest progress [54]. Consistently, CSC-like populations 
have been described in NB tumor samples and cell 
lines, presenting expression of stem-like genes and high 
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tumorigenicity [55, 56]. NC progenitor cells described in 
our work are enriched in genes previously described in 
NC stem cells, such as BMI1, OCT4 and MSI1 [37, 38]. 
Moreover, these NC progenitor cells can differentiate into 
both neural (positive for GFAP, S100b, DDC or Tuj1) and 
mesectodermal cells (positive for CD105, CD44, MSCA1 
or SMA) in vitro. However, the absence of tumorigenicity 
under our experimental conditions rule out the possibility 
of considering these cells similar to previously described 
cell populations of NB CSCs. Instead, our culture 
conditions selected for mesenchymal-like cells lacking 
critical genomic alterations when compared to their 
original tumor biopsies. Our results are compatible 
with the isolation of non-tumorigenic undifferentiated 
NC progenitor cells. These cells divide and give rise to 
stromal-like cells when cultured in vitro, contributing to 
tumor stroma formation and aggressiveness in a mouse 
model of NB. Future research should determine how 
general is this phenomenon of non-tumorigenic stem/
progenitor cells being included in tumors [57], and should 
study the role of such cell population in tumor biology.
During the last years, tumor stroma has emerged 
as a key player in the biology of most types of cancers. 
In addition to highly proliferative tumorigenic cells, 
tumors are composed by a variety of non-tumorigenic 
cell types such as endothelial cells, pericytes, immune 
cells or cancer-associated fibroblasts (CAFs). Together 
with the extracellular matrix, these cells constitute the 
tumor microenvironment and promote aggressiveness, 
participating in processes such as tumor growth, 
metastasis, inflammation or angiogenesis [4–9].
Since NC stem cell populations have been 
described in several adult neural crest derived tissues 
[12], a likely explanation to our results could be that 
some NC progenitors get confined to the aberrant niche 
being orchestrated by transformed neuroblasts during 
NB tumor formation. These NC progenitors could easily 
contribute to tumor stroma due to their capacity to give 
rise to NC-typical mesectodermal derivatives. Consistent 
with this, we demonstrate that supplementation with 
NC derived stromal cells promotes proliferation and 
tumor aggressiveness in vivo, increasing expression of 
mesenchymal genes such as CD44, S100A10, ENG, VIM 
and ACTA2 (SMA), being the last one a typical marker of 
CAFs [4, 9].
CAF content and gene expression profiles related 
to mesenchymal features have been previously associated 
to agressiveness and poor prognosis in high-risk NBs 
[10, 11]. Nevertheless, the origin and function of these 
stromal cells remain unknown. In our work, we propose 
a major role for NC derived non-tumorigenic progenitor 
cells in the formation of such stromal compartment in 
aggressive NB. In line with this, in silico analysis of gene 
expression profiles from available tumor series confirmed 
the existence of a neural crest stem cell (NCSC) gene 
signature [13] associated to mesenchymal features and 
agressiveness in NB. K-means clustering of NB tumors 
based on the expression of NCSC genes resulted in three 
different groups with high (NCH), intermediate (NCI) 
and low (NCL) expression of this signature. Interestingly, 
Figure 5: A neural crest stem cell (NCSC) gene signature segregates stage 4/M NB tumors and is associated to tumor 
aggressiveness. (A-D) NCSC gene signature defines a subgroup of stage 4/M NB tumors with high probability of relapse. (A) K-means 
clustering using genes up-regulated in NCSCs (described in Lee et al. [13]), segregating stage 4/M NB tumors into three different groups 
depending on high, intermediate or low expression levels of the signature (NCH, NCI and NCL tumors respectively). (B) NCH tumors are 
enriched in NCSC genes related to the mesenchymal phenotype of the neural crest, such as TGFB1, EDNRA and S100A10. By contrast, 
genes related to neural specification of NCSCs, such as SCG3, POU4F1 and PHOX2B, show lower expression levels within NCH tumors. 
(C) Transcriptome wide profiling by principal component analysis, revealing a clear segregation between NCH, NCI and NCL tumors. 
Principal component 2 (PC2) maximized the differences between the three types of tumors. (D) Kaplan-Meier curves showing event-free 
survival probability of NCH, NCI and NCL tumors, compared to all stage 4/M tumors analyzed together. NCH and NCL tumors present 
higher probability of relapse compared to NCI neuroblastomas. (E-H) NCH express higher level of mesenchymal related genes. (E) 
Expression levels of typical mesenchymal genes in NCH tumors compared to NCI and NCL tumors together (NCL+I). All genes analyzed 
(NT5E, ENG, CD44, PDGFRA, ACTA2, VIM, CSCL12 and SPARC) showed higher expression levels in NCH tumors than in NCL+I 
tumors. (F) Parametric analysis of gene set enrichment (PAGE) in NCH tumors revealed enrichment in the expression of genes previously 
described as characteristic of a mesenchymal phenotype. Enrichment z-score for three different gene sets is shown: genes typical of the 
mesenchymal subtype in glioblastoma (gene set #1, described in Verhaak et al.[48]), genes up-regulated in stromal stem cells (gene set 
#2, described in Boquest et al. [50]), and genes typical of mesenchymal transition in cancer (gene set  #3, described in Anastassiou et 
al. [49]). The heat map in the upper panel shows the complete gene set map of average z-scores for all genes in every single gene set, 
calculated for each individual sample. (G) Box-whiskers plots showing the expression of the three different gene sets analyzed in NCH, 
but now compared to NCL+I tumors. (H) Correlation between gene set enrichment average z-scores in individual tumors over the whole 
sample of tumors analyzed. NCSC z-scores were correlated to enrichment z-scores for the gene sets analyzed in (F). The results revealed 
a close correlation between expression of genes up-regulated in NCSCs and genes related to mesenchymal features, both being highly 
expressed in NCH tumors.  (I, J) Genes differentially expressed in NCH tumors are involved in biofunctions and processes related to the 
stromal component of tumors. (I) Representative biofunctions and processes resulting from gene ontology analysis of genes differentially 
expressed between NCH and NCL+I tumors. Genes overexpressed in NCH tumors participate preferentially in processes related to the 
stromal component of tumors, such as “positive regulation of immune response”, “extracellular matrix organization” and “angiogenesis”. 
(J) Heat map showing the expression levels of genes involved in angiogenesis (GO Path 1525). Tumors are hierarchically clustered and 
NCSC enrichment status is shown in the upper bar. Whiskers in Box-Whiskers plots indicate maximum and minimum values. (r-value = 
Pearson’s correlation coefficient) (****p < 10–4, ***p < 0.001, **p < 0.01; Mann-Whitney U-test).
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NCH and NCL tumors showed increased probability 
of relapse compared to NCI tumors. Moreover, PAGE 
analysis demonstrated that NCH tumors were enriched in 
expression of genes clearly associated to a mesenchymal 
phenotype [48–50] . Gene ontology analysis revealed that 
genes overexpressed in NCH tumors were associated to 
biofunctions related to the stromal component of tumors, 
such as “extracellular matrix organization”, “immune 
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response” or “angiogenesis”. In contrast, NCL tumor 
overexpressed genes are involved in functions related to 
cell proliferation and metabolism (data not shown). Our 
data also illustrate the correlation existing between SMA 
expression and poor prognosis in NB tumors. Moreover, 
we also demonstrate that high expression levels of NCSC 
gene signature correlate with high expression levels of 
ACTA2 (the gene encoding for SMA) in stage 4/M tumors. 
These results support the idea that elevated expression of 
mesenchymal genes observed in NCH tumors is mainly 
due to the presence of stromal cells being differentiated 
from NC progenitor cells.
Currently, one of the major challenges in NB 
research is to improve therapeutic strategies in aggressive 
tumors [3]. In our opinion, enrichment in NCSC gene 
signature and correlation to SMA expression could 
be useful to improve stratification of stage 4/M NBs. 
Tumors with high content of NC-derived stroma could 
be treated with novel therapeutic approaches targeting 
stroma-associated processes, such as immune response, 
cell migration or angiogenesis. Distinguishing these NC 
progenitor cell-containing tumors (NCH) from NCL 
tumors, in which aggressiveness more likely depends on 
tumorigenic neuroblast autonomous processes such as 
cell cycle, proliferation and metabolism, might also help 
devise better treatments for aggressive heterogeneous NB.
MATERIALS AND METHODS
Tumor dispersion and primary adherent cell 
cultures
The Hospital Virgen del Rocío Ethics Committee 
previously approved all protocols involving manipulation 
of human samples, and proper informed consents were 
obtained from subjects’ guardians. Patient-derived 
neuroblastoma fresh tumor samples (see Supplementary 
Table 1) were managed and obtained from Hospital 
Universitario Virgen del Rocío/Instituto de Biomedicina 
de Sevilla Biobank (Andalusian Public Health System 
Biobank and ISCIII-Red de Biobancos PT13/0010/0056). 
After discarding non-viable tissue, tumor samples were 
minced into small pieces (2–4 mm), washed with cold 
PBS (GIBCO) and enzymatically dissociated. Tumor 
fragments were incubated on dissociation solution (0.6 
mg/mL Collagenase (Sigma-Aldrich), 0.05 mg/mL 
Elastase (Calbiochem, Merck Chemicals Ltd), 0.3 mg/
mL Trypsin (Sigma-Aldrich) and 0.32 mg/mL DNAse I 
(Sigma-Aldrich), in HBSS buffer (GIBCO) in agitation 
at 37ºC during 15–30 minutes.  Tumor dispersion was 
completed mechanically by pipetting up and down. 
Then, cold fresh culture medium was added to stop the 
enzymatic reaction, and the resulting solution was filtered 
through a 70 µm cell strainer (BD Biosciences).  When 
necessary, cell suspension was incubated 2–3 times 
in ACK buffer (155 mM NH4Cl, 2.96 mM NaHCO3 
and 3.72 mM EDTA·4H2O) to eliminate erythrocytes. 
After that, viable cells were counted and seeded at the 
desire density in neural crest (NC) culture medium 
[14] containing DMEM:F-12 (GIBCO) with 15% fetal 
bovine serum (GIBCO), 1% N2 supplement (GIBCO), 
1% B27 supplement (GIBCO), 100U penicillin:100mg 
streptomycin (GIBCO) per mL, 20 ng/ml recombinant 
human bFGF (R&D Systems), 20 ng/ml recombinant 
human IGF-1 (R&D Systems), and 20 ng/ml recombinant 
human EGF (R&D Systems).
Sphere culture and differentiation protocol
Cells obtained after tumor dispersion were seeded 
in ultra low binding culture plates (Corning Inc.) at 
a density of 3 × 104 – 5 × 104 cells/ml in NC medium. 
To obtain spheres from established NB primary cell 
lines, after detaching cells from substrate using trypsin 
(Sigma-Aldrich), they were seeded in ultralow binding 
6-well plates (Corning Inc.) at a clonal density of 5 × 
103 – 1 × 104 cells/mL in NC medium. After 4–5 days in 
culture, spheres were passed to fresh NC medium. For all 
the experiments, spheres were grown for a minimum of 5 
and a maximum of 10 days. For differentiation, after 4–5 
days in culture, spheres were passed to fresh NC medium 
with or without serum and cultured for another 4–5 days 
Figure 6. SMA correlates to NCSC gene signature expression and aggressiveness in stage 4/M NBs. (A-D) Association between SMA 
protein expression and histopathological features typical of stage 4/M NBs. (A) Representative images of anti-SMA immunohistochemistry in 
sections from Stage 1–2 vs. Stage 4 tumors. Scale bars: 100 μm. (B) Expression of SMA (% of stained area) was calculated as in figure (4I). 
Aggressive neuroblastomas (Stage 4/M) showed higher expression levels than low-risk tumors (Stage 1 and 2). (C) Representative images 
of anti-SMA immunohistochemistry in stage 4/M tumor sections before and after treatment. Scale bars: 100 μm. (D) Quantification of SMA 
expression (% of stained area) in pre- and post-treatment tumor sections. Concomitantly to treatment-induced tumor differentiation (considered 
as an indicator of treatment response), we observed a significant decrease in SMA expression levels. (E) ACTA2 (gene encoding for SMA) 
expression correlates with mesenchymal genes (ENG, TGFB1, S100A10 and VIM). (F) Parametric analysis of gene set enrichment (PAGE) 
revealed that tumors with higher expression of ACTA2 were also enriched in expression of typical NCSC genes (gene set #1, described in Lee 
et al.[13]) and MSC genes (gene set #2, described in Boquest et al.[50]). Heat map (upper panel) shows the average z-scores for all genes in 
every single gene set, calculated for each individual tumor sample. (G) Quantification of the expression of NCSC or MSC gene signatures in 
ACTA2 high compared to ACTA2 low tumors. (H) Correlation between ACTA2 expression and NCSC gene signature average z-scores over 
the whole sample of tumors analyzed. (I) Tumors enriched in expression of NCSC genes (NCH) show higher expression levels of ACTA2. (J) 
Kaplan-Meier curves showing the association between high ACTA2 expression levels and lower event-free survival probability. (K) Kaplan-
Meier curves showing the event-free survival probability of NCI tumors segregated into ACTA2 high (48%) and ACTA2 low (52%) tumors. 
(r-value = Pearson’s correlation coefficient) (****p < 10–4, *p < 0.05; Mann-Whitney U-test). See also Supplementary Figure 6.
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in low binding culture plates. After that, spheres were 
passed to culture plates treated with 1–5 μg/cm2 of human 
fibronectin (Biomedical Technologies Inc.) and culture 
medium (with or without serum) was replaced. This step 
allowed spheres to attach to the substrate and grow in 
adherent conditions for another 4–5 days. Then, cells were 
fixed and analyzed by immunocytochemistry.
Cell lines
IMR32, SK-N-SH and SK-N-DZ neuroblastoma 
cell lines were obtained from The American Type Culture 
Collection (ATCC) repository, and were cultured in 
Dulbecco’s modified Eagle medium (DMEM; GIBCO), 
supplemented with 10% fetal bovine serum (FBS; 
GIBCO) and 100U penicillin:100mg streptomycin 
(GIBCO) per mL, at 37ºC and 5% CO2. Neuroblastoma 
cell line SK-N-AS was obtained from the repository at 
Hospital Sant Joan de Déu (Barcelona, Spain). This line 
was grown in Roswell Park Memorial Institute (RPMI)-
1640 medium supplemented with 10% FBS (Invitrogen), 2 
mM L-glutamine, penicillin (100 U/mL) and streptomycin 
(100 µg/mL) (GIBCO), at 37ºC and 5% CO2.  Human 
fibroblasts (hFIB) cell line CCD 1112Sk was obtained 
from The American Type Culture Collection (ATCC) and 
cultured in Dulbecco’s modified Eagle medium (DMEM; 
GIBCO), supplemented with 10% FBS (GIBCO) and 
100U penicillin:100mg streptomycin (GIBCO) per mL, at 
37ºC and 5% CO2. Stable NB5t-EGFP or IMR32-RFP cell 
lines were obtained by transfection of lentiviral vectors 
expressing EGFP or RFP. For the co-cultures, IMR32-RFP 
and NB5t cells were mixed at 1:1 ratio and cultured onto 
adherent. The inhibitors AMD3100 (Sigma) and PAN-
TGFβ (MAB1835; R&D Systems) were added at 20µM 
and 8mg/ml final concentrations, respectively.
ET-1 treatment
Primary adherent cell lines cultured in NC medium 
were treated daily with 25 ng/mL ET-1 (Sigma-Aldrich) 
during 7 days and then fixed. Spheres were cultured in 
NC medium with low serum (1.5%) and treated daily 
with the same ET-1 concentration during 7 days. After 
that, we measured the number and diameter of the spheres 
and collected them for mRNA expression analysis. To 
determine the specificity of ET-1 effect in sphere cultures, 
endothelin receptors were blocked using Bosentan (gift 
from Actelion Pharmaceuticals). Bosentan was added 




Immunocytochemical and immunohistochemical 
stainings were performed following standard procedures. 
For details, see Supplementary Methods.
Flow cytometry
Flow cytometric analyses were performed in a BD 
LSRFortessaTM cytometer (BD Bioscience), following 
standard procedures. For details, see Supplementary 
Methods.
Total mRNA expression and gene ontology 
analysis
Total RNA was extracted from unfixed primary 
adherent cell lines and spheres using the RNeasy Mini 
Kit (Qiagen) following manufacturer’s instructions. 
mRNA expression analysis was performed using 
GeneChip® PrimeViewTM Human Gene Expression 
Arrays (Affymetrix). Expression changes induced by 
endothelin-1 treatment were determined by comparing the 
expression profiles of spheres obtained from 3 different 
primary cell cultures (NB5t, NB14t and NB27t) with or 
without ET-1 treatment. For each condition, we extracted 
and pooled the same quantity of total mRNA from 3 
independent experiments. Results were analyzed using 
the Transcriptome Analysis Console (TAC) Software 
(Affymetrix), revealing changes in 660 probes (fold 
change > 1.5 and p-value < 0.05). To obtain biological 
significance from expression data, we performed a gene 
ontology analysis of differentially expressed genes using 
the Ingenuity Pathway Analysis (IPA) online toolkit 
(Ingenuity). Z-score is based on the direction of fold 
change values for genes in the input data set for which 
a correlation has been established in the Ingenuity 
Knowledge Database. Z-score > 2 predicts an increase 
in the activation state of cell function. All microarray 
rough analysis files are available from the GEO (http://
www.ncbi.nlm.nih.gov/geo) database (accession number 
GSE78268).
Quantitative real-time PCRs
Total RNA was extracted from unfixed cell 
cultures and tumor-derived tissues by RNeasy Mini Kit 
(Qiagen) following manufacturer’s recommendations. 
Complementary DNA was generated using qScript™ 
cDNA SuperMix (Quanta Biosciences). PCRs were 
performed on ABI Prism 7700 Sequence Detector 
(Applied Biosystems) using Fast SYBR Green Master 
Mix (Applied Biosystem) and specific primers (listed in 
Supplementary Table 5) at a final concentration of 300 
nM. In all samples, each gene was quantified at least in 
duplicate. Data were analyzed using the 2-ΔΔCt method 
using GAPDH gene as housekeeping for normalization.
Xenografts
All procedures involving mice were performed 
according to the animal care guidelines of the European 
Community Council (86/609/EEC) and were approved 
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by the Animal Research Committee at the Instituto de 
Biomedicina de Sevilla/Hospital Universitario Virgen 
del Rocío (Sevilla, Spain). Xenografts were performed in 
six-week-old C.B-17 SCID mice (C.B-17/IcrHan®Hsd-
Prkdcscid, Harlan Laboratories).
Heterotopic xenografts
 5x105 neuroblastoma cells (IMR32 cell line) were 
injected subcutaneously in SCID mice, alone or with EGFP 
expressing primary cells from NB5t sample at a 1:1 ratio. 
For injection, cells were resuspended in a final volume of 
100 μl: 50 μl of PBS (GIBCO) containing the cells were 
mixed with 50 μl of Matrigel (Corning Incorporated) and 
injected subcutaneously using a 29-gauge needle. After 
45–60 days, animals were sacrificed and tumors were 
removed and processed as indicated above.
Orthotopic xenografts
Female mice were anaesthetized using 100 mg/
Kg ketamine and 5 mg/Kg diazepam injected intra-
peritoneally. Orthotopic implantation was performed 
through ventrolateral incision. A total of 1x106 NB cells 
in 10 μl of PBS (GIBCO) were injected in the left adrenal 
gland using a 33-gauge needle connected to a 10 μl 701 RN 
SYR syringe (Hamilton). Abdominal wall and skin were 
closed with absorbable suture (VICRYL 4/0, Ethicon) and 
silk suture (SILKAM 4/0, Braun surgical) respectively. 
After surgery, the animals were treated with 1mg/Kg 
flumazenil injected intramuscularly to revert the effect of 
diazepam, and were analgesized with 0.3 mg/Kg meloxicam 
injected subcutaneously. Xenografted animals were usually 
sacrificed after one month. Exceptionally, and only in those 
cases in which we injected tumor-derived primary cells that 
finally were revealed as non-tumorigenic, we waited up to 
six months before seeking for tumor formation.
Determination of haploid MYCN copy number 
by quantitative real-time PCR (qPCR)
Genomic DNA from adherent primary cell cultures 
and commercial NB cell lines was isolated using the 
GenEluteTM Mammalian Genomic DNA miniprep kit 
(Sigma-Aldrich) following manufacturer’s instructions. 
Analysis of MYCN amplification status was performed 
by means of qPCR using TaqMan detection chemistry 
as previously described [58]. Briefly, MYCN and two 
reference genes, BCMA and SDC4, were simultaneously 
amplified in separate tubes for each tumor sample. PCR 
reactions were performed on an ABI Prism Sequence 
Detection System 7500 SDS (Applied Biosystems). 
Duplicate amplification mixtures for each sample (10 µL) 
were prepared for MYCN, BCMA and SDC4 quantification, 
and contained genomic DNA (10 ng), Taqman mix, 
300 nM of each primer, and 200 nM of the probe. Haploid 
MYCN copy number was calculated according to 2-ΔΔCt 
method. Genomic DNA from neuroblastoma cell line LA-
N-1 was used as positive control for MYCN amplification. 
Genomic DNA isolated from blood of 3 healthy donors 
was pooled and used as calibrator sample.
Multiplex ligation-dependent probe 
amplification (MLPA)
Genomic DNA from different samples was isolated 
using the GenEluteTM Mammalian Genomic DNA 
miniprep kit (Sigma-Aldrich) following manufacturer’s 
instructions. Quantification of losses, gains and 
amplifications were determined by multiple ligation- 
dependent probe amplification (MLPA) according to 
the methods previously reported [59]. Each genomic 
DNA sample was amplified and analyzed using the 
neuroblastoma-specific MLPA kit SALSA P251-B1 (MRC 
Holland), which contains 34 probes for chromosomes 1, 3, 
and 11, as per manufacturer’s instructions. Genomic DNA 
from peripheral blood of 3 healthy donors was pooled and 
used as reference. Also, DNA from neuroblastoma cell line 
SK-N-AS was used as positive control.
Bioinformatic analysis of neuroblastoma tumor 
series
All bioinformatic analyses were performed in silico 
using expression data from tumor series stored in the R2 
bioinformatic platform, available from the public website 
http://R2.amc.nl. Details about these analyses are given in 
Supplementary Methods.
Statistics
Bar charts represent mean ± S.E.M. Box and whisker 
plots represent the median (line), 25% and 75% percentiles 
(box), and minimum and maximum values (whiskers). In 
Figures 1–3 and Supplementary Figure 3, (n) represents 
technical replicates, while biological replicates are shown 
as individual symbols. In Figures 4–6 (n) represents 
biological replicates. Statistical and correlation tests are 
indicated in each case. All statistics were performed using 
Prism 6.0 (GraphPad Software), except Kaplan-Meier 
curves, PAGE analysis and Gene Ontology studies, in 
which statistical significance was provided automatically 
by the on-line software R2 analysis and visualization 
platform (http://R2.amc.nl), or by the Ingenuity Pathway 
Analysis on-line toolkit.  For data shown in Figure 3H, we 
previously eliminated outliers by applying the Grubbs’ test 
(alpha = 0.05).
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